Abstract
Background: Gliomas are primary cerebral tumors. Radiation therapy plays a key role in their treatment but with a risk of toxicity associated with the dose to and volume of normal tissue that is irradiated. With its precision properties allowing for the increased sparing of healthy tissue, proton therapy could be an interesting option for this pathology. Methods: Two reviewers performed a systematic review of original papers published between 2010 and July 2021 following PRISMA guidelines. We analyzed disease outcomes, toxicity outcomes, or dosimetry data in four separate groups: children/adults and individuals with low-/high-grade gliomas. Results: Among 15 studies, 11 concerned clinical and toxicity outcomes, and 4 reported dosimetry data. Proton therapy showed similar disease outcomes with greater tolerance than conventional radiation therapy, partly due to the better dosimetry plans. Conclusions: This review suggests that proton therapy is a promising technique for glioma treatment. However, studies with a high level of evidence are still needed to validate this finding.
Highlights
After checking the references of these articles, four other studies were considered eligible for our review for a total of 15 original papers
Results of the update by Tabrizi et al confirmed excellent Proton therapy (PRT) tolerance. They demonstrated that neuroendocrine deficiencies tended to be more common in patients who received ≥ 20 Gy RBE to the hypothalamus or pituitary (p = 0.142), with an inverse relationship between dose and time of onset [20]
Bronk et al reported PsP outcomes of 36 patients with LGG treated with intensity-modulated RT (IMRT) (50%)
Summary
Methods: Two reviewers performed a systematic review of original papers published between 2010 and July 2021 following PRISMA guidelines. Toxicity outcomes, or dosimetry data in four separate groups: children/adults and individuals with low-/high-grade gliomas. Results: Among 15 studies, 11 concerned clinical and toxicity outcomes, and 4 reported dosimetry data. Proton therapy showed similar disease outcomes with greater tolerance than conventional radiation therapy, partly due to the better dosimetry plans. Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. Gliomas are brain tumors that develop from glial cells, usually oligodendrocytes and astrocytes. Their yearly incidence is approximately 5 cases per 100,000 habitants, and they may develop at any age [1].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
